- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02629926
Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors
A Phase IV, Single-Centre, Non-Randomised, Controlled, Open-Label Study to Assess the Use of Growth Hormone (GH) Replacement Therapy (NutropinAq®) During Transition in GH Deficient Survivors of Childhood Cancer to Optimise Somatic Growth & Well-Being
Cure rates for childhood malignancies have improved at a remarkable pace.With the increasing cure rate came recognition of the long-term detrimental effects of radiotherapy and chemotherapy, known as "late-effects". Endocrine late-effects are particularly prevalent in childhood cancer survivors. Growth Hormone (GH) deficiency is common following radiation to the head and leads to impaired growth, hence GH replacement is given to achieve optimise final height in childhood. In the adult GH is important to maintenance of bone, muscle & fat mass; vascular risk factors; and quality of life. This observational study aims to determine the long-term effect of low dose GH replacement on development of bone, muscle and fat mass; vascular risk; and quality of life in the early years after achievement of final height, a time known as "transition". GH is thought to be essential to development of bone, muscle, and fat mass during this time period.
Patients will be identified in the late -effects endocrine clinic, aged 16-22yrs, who are severely GH deficient. 30 patients will be recruited to the study who wish to continue receiving GH replacement, all of whom will receive recombinant GH. An additional 30 patients who do not wish to receive GH replacement will provide a parallel control data.
All patients will undergo baseline assessment including examination; routine blood tests; urine dipstick; measures on height, weight, waist, and 24 hour blood pressure. Measures will be repeated at six months, and then annually until 25 years of age. Bone density will be measured at baseline, after two years and at age 25yrs. Patients requesting GH replacement will require initial additional visits to teach self injection, then 2-4wkly to assess when correct dose of GH is achieved. The study will enable assessment of the beneficial effects of GH replacement during transition in GH deficient survivors of cancer to be realised.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Leeds, United Kingdom, LS9 7TF
- Recruiting
- The Leeds Teaching Hospitals Nhs Trust
-
Contact:
- R&I Administrator
- Phone Number: 0113 392 0152
- Email: leedsth-tr.lthtresearch@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 16--22 years inclusive.
- Both genders.
- Able to provide informed consent.
- Severe GH deficiency (peak GH<5mcg/l on stimulation).
- No GH replacement therapy during the three months preceding the baseline visit.
- Stable anterior pituitary hormone (i.e. sex steroids, hydrocortisone, thyroxine) therapy over the previous six months.
- Life expectancy >24 months.
Exclusion Criteria:
- Acute critical illness (Patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure, or similar conditions).
- Active malignant disease (i.e. undergoing active treatment or palliation).
- Patients treated for an intracranial malignancy should have completed therapy two years prior to entering the study.
- Active Cushing's disese or acromegaly
- Pregnancy or desire to conceive within the following year. Patients at risk of pregnancy will be screened by urine pregnancy (HCG) test at the baseline evaluation & treatment initiation visit.
- Breast feeding.
- Proliferative diabetic retinopathy.
- Sensitivity to GH or its preservative
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients to receive GH replacement
30 patients will be recruited to the study who wishes to continue receiving growth hormone replacement, all of whom will receive NutorpinAq Recombinant growth hormone
|
GH Replacement continued.
|
Patients who will not receive GH replacement
An additional 30 patients who elect not to receive growth hormone replacement will provide a parallel control data.
|
GH Replacement not continued.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare the change in quality of life (QoL) at twelve months with that at baseline for the two treatment groups. For the primary endpoint this will be determined using the GH -specific instrument, the Adult Growth
Time Frame: 12 monthly intervals until the age of 25yrs
|
12 monthly intervals until the age of 25yrs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
compare the change in QoL at each assessment timepoint versus to Baseline for the two treatment groups
Time Frame: 12 monthly intervals until the age of 25yrs
|
three generic selfrating questionnaires
|
12 monthly intervals until the age of 25yrs
|
Psychological General WellBeing Schedule (PGWBS)
Time Frame: 12 monthly intervals until the age of 25yrs
|
Questionnaire completed at 12 months
|
12 monthly intervals until the age of 25yrs
|
Shortform 36 (SF36) questionnaire
Time Frame: 12 monthly intervals until the age of 25yrs
|
Questionnaire completed at 12 months
|
12 monthly intervals until the age of 25yrs
|
EuroQoL 5D (EQ5D) questionnaire
Time Frame: 12 monthly intervals until the age of 25yrs
|
AGHDA SF36 PGWBS EQ5D
|
12 monthly intervals until the age of 25yrs
|
compare the change in body composition between the two treatment groups at each assessment timepoint versus Baseline.
Time Frame: 12 monthly intervals until the age of 25yrs
|
Weight Height Waist & hip circumference Skin thickness Bioimpedance Total body DXA scan
|
12 monthly intervals until the age of 25yrs
|
compare the change in cardiovascular risk factors between the two treatment groups at each assessment every 12 months versus Baseline.
Time Frame: 12 monthly intervals until the age of 25yrs
|
12 monthly intervals until the age of 25yrs
|
|
compare the change in bone mineral content between the two treatment groups at each assessment every 12 months versus Baseline.
Time Frame: 12 monthly intervals until the age of 25yrs
|
12 monthly intervals until the age of 25yrs
|
|
compare the change in bone turnover between the two treatment groups at each assessment timepoint versus Baseline.
Time Frame: 12 monthly intervals until the age of 25yrs
|
Measurements of: DXA Scan
|
12 monthly intervals until the age of 25yrs
|
To assess the safety of GH treatment (IGF-I, Blood glucose, HbA1C, Blood pressure, Side effect questionnaire, Adverse events, Scheduled or unscheduled laboratory findings, Changes in concomitant medication)
Time Frame: 12 monthly intervals until the age of 25yrs
|
IGF-I Blood glucose HbA1C Blood pressure Side effect questionnaire Adverse events Scheduled or unscheduled laboratory findings Changes in concomitant medication
|
12 monthly intervals until the age of 25yrs
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ED07/8440
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Diseases
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic DisorderAustralia
-
Asia UniversityDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
San Diego State UniversityRecruitingBone Disease, MetabolicUnited States
-
Nantes University HospitalCentre de Recherche en Nutrition Humaine Ouest (CRNH)CompletedCholesterol; Metabolic Disorder | LipoproteinemiaFrance
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
-
University Hospital, Basel, SwitzerlandCompletedMetabolic DiseaseSwitzerland
-
Maastricht University Medical CenterCompleted
Clinical Trials on GH Replacement (NutropinAq®)
-
Karolinska University HospitalCompleted
-
IpsenTerminatedrhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 DeficiencyInsulin-like Growth Factor-1 DeficiencyUnited States
-
Globus Medical IncCompletedLumbar Spinal StenosisUnited States, Puerto Rico
-
Shanghai Cingularbio Co. LtdCompleted
-
Spinal Stabilization TechnologiesActive, not recruitingChronic Low-back Pain | Degenerative Disc DiseaseCanada, Croatia, Belgium, Germany
-
NuVasiveTerminatedCervical Disc DiseaseMexico
-
Shanghai MicroPort CardioFlow Medtech Co., Ltd.Not yet recruitingAortic Valve Stenosis | Aortic Valve DiseaseChina
-
Taewoong Medical Co., Ltd.Active, not recruitingPulmonary Valve Stenosis | Congenital Heart Defect | Pulmonary Valve; Insufficiency, CongenitalKorea, Republic of
-
Restor3DCompletedOsteoarthritis,KneeUnited States